1
|
Imber BS, Bodei L, Humm J, Ionescu A, Wu W, Grkovski M, O'Donoghue J, Reddy RP, Rimner A, Shasha D, Zhang Z, Schoder H, Morris M, Zelefsky MJ. A Pilot Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for Oligometastatic Hormone Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e112. [PMID: 37784650 DOI: 10.1016/j.ijrobp.2023.06.891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Stereotactic body radiotherapy (SBRT) is increasingly used for oligorecurrent prostate cancer (OPC). Despite excellent local control, distant metastasis free survival rates are more modest. We hypothesized SBRT outcomes could be optimized with improved staging imaging and integration of a well-tolerated targeted radiopharmaceutical therapy (RLT) for microscopic disease. We report initial results of a prospective, single-institution pilot (NCT05079698) of a novel, PSMA-based theranostic strategy for OPC. MATERIALS/METHODS Men with castrate sensitive OPC and 1-3 sites of PSMA PET avid disease ("index lesions") and no PSMA non-avid sites were eligible. No androgen deprivation therapy was permitted. Subjects first received 2 cycles of 177Lu-PSMA-617 RLT (7.47±0.14 GBq) spaced 6 weeks apart. In vivo dosimetry was performed during cycle 1. Four weeks post-cycle 2, patients were restaged with 68Ga-PSMA PET for an interim (post-RLT) response assessment. Index lesions were then consolidated with SBRT (9 Gy x 3) irrespective of post-RLT PET response. The primary outcome was feasibility defined as successful completion of protocol-mandated therapy without intercurrent distant failure on post-RLT PET. RESULTS Six men were treated with nine total index lesions (5 nodal, 3 osseous, 1 visceral). The study met its primary endpoint; all completed required interventions and no distant progression was seen on interim PSMA PET. Treatment was well tolerated; no grade 3+ toxicities, 2/6 had grade 2 toxicities (transient anemia and hyperbilirubinemia) and 5/6 had grade 1 toxicities. Median baseline lesion-level PSMA SUVmax was 16.8±8.7. Median interim SUVmax was 6.2±2.5 and declined for all but one lesion post-RLT (median -65%). Median SUVmax at 3-mos post-SBRT was 3.3±2.5 and decreased for all evaluable lesions (median -80%). Median baseline PSA was 2.01 ng/mL (range: 0.72-4.56) which declined in 5/6 post-RLT. The 6th patient experienced biochemical rise with interim PET showing only greater avidity in the known index lesion and SBRT was completed per protocol. All 4 evaluable patients with at least one post-SBRT follow-up have improved PSA at last visit (range 5.5-12 mos from cycle 1), and 2/4 have undetectable PSA. Composite dosimetry, correlatives and quality of life studies are forthcoming. CONCLUSION Our pilot study demonstrates the feasibility of a novel PSMA anchored theranostic strategy combining SBRT with targeted RLT for OPC. Preliminary data suggests promising outcomes, including the possibility of achieving an undetectable biochemical disease state without hormone therapy.
Collapse
Affiliation(s)
- B S Imber
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - L Bodei
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - J Humm
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Ionescu
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - W Wu
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Grkovski
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - J O'Donoghue
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - R P Reddy
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Rimner
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - D Shasha
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Z Zhang
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - H Schoder
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Morris
- Memorial Sloan Kettering Cancer Center, New York, NY
| | - M J Zelefsky
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
2
|
Han J, Diplas B, Paudyal R, Oh J, Sherman E, Schoder H, Hatzoglou V, Yu Y, Wong R, Wray R, Boyle J, Grkovski M, Humm J, Dave A, Riaz N, Lee N. Tumor Volume Predicts for Baseline Hypoxia Status in HPV Related Oropharyngeal Carcinomas (OPC) that Underwent Major Radiation De-escalation: The 30 Reduction in Oropharyngeal Cancer Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
3
|
Diplas B, Han J, Paudyal R, Oh J, Sherman E, Schoder H, Hatzoglou V, Yu Y, Wong R, Wray R, Boyle J, Grkovski M, Humm J, Dave A, Riaz N, Lee N. Intra-Treatment Tumor Apparent Diffusion Coefficient, a Quantitative Imaging Metric, is Associated with Neck Nodal Recurrence in De-Escalated Treatment of HPV-Positive Oropharyngeal Cancer (OPC). Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
4
|
Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez‐Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schoder H, Seshan VE, Salles G, Younes A, Batlevi CL. CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.32_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Sha
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - M. Okwali
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. Alperovich
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - P. C. Caron
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - L. Falchi
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. Hamilton
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - P. A. Hamlin
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - S. M. Horwitz
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - E. Joffe
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. Kumar
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - M. J. Matasar
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. J. Moskowitz
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. Noy
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - C. Owens
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - L. M. Palomba
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | | | - D. Straus
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - G. von Keudell
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. D. Zelenetz
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - J. Yahalom
- Memorial Sloan Kettering Cancer Center Radiation Oncology, New York New York USA
| | - A. Dogan
- Memorial Sloan Kettering Cancer Center Pathology, New York New York USA
| | - H. Schoder
- Memorial Sloan Kettering Cancer Center Radiology, New York New York USA
| | - V. E. Seshan
- Memorial Sloan Kettering Cancer Center Epidemiology and Biostatistics New York USA
| | - G. Salles
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| | - A. Younes
- Memorial Sloan Kettering Cancer Center Medicine; Currently employed at AstraZeneca New York USA
| | - C. L. Batlevi
- Memorial Sloan Kettering Cancer Center Medicine New York USA
| |
Collapse
|
5
|
Sanduleanu S, Tamanupadhaya@gmail.com T, Klaassen R, Woodruff H, Hatt M, Kaanders J, Vrieze O, Laarhoven H, Subramiam R, Huang S, Bratman S, Dubois L, Miclea R, Di Perri D, Geets X, Crispin-Ortuzar M, Aptea A, Hun Oh J, Lee N, Humm J, Schoder H, Ruysscher D, Hoebers F, Lambin P. PO-1583: Non-invasive radiomic imaging prediction of tumour hypoxia: biomarker for FLASH irradiation? Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01601-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Riaz N, Sherman E, Pei X, Schoder H, Paudyal R, Katabi N, Ma D, Tsai C, McBride S, Morris L, Boyle J, Singh B, Foote R, Ho A, Wong R, Humm J, Dave A, Pfister D, Reis-Filho J, Lee N. Genetic and micro-environmental factors influencing response to definitive 30Gy chemo-radiotherapy (chemoRT) in HPV Positive Oropharyngeal Cancer (OPC). Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Sauter C, Lin R, Ho C, Devlin S, Maloy M, Perales M, Dahi P, Schoder H, Jakubowski A, Barker J, Papadopoulos E, Giralt S. ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPACTS ON IMMUNE EVASIVE MECHANISMS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A SINGLE CENTER EXPERIENCE. Hematol Oncol 2019. [DOI: 10.1002/hon.113_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C.S. Sauter
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - R.J. Lin
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Ho
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Devlin
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.A. Maloy
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Perales
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P.B. Dahi
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - H. Schoder
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.A. Jakubowski
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - J.N. Barker
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - E.B. Papadopoulos
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.A. Giralt
- Medicine; Adult BMT Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
8
|
Morikawa A, Jhaveri K, Grkovski M, Tang K, Humm JL, Holodny A, Beal K, Schoder H, Seidman AD. Abstract P1-19-03: A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-19-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: WBRT is a standard therapy for metastatic breast cancer (MBC) patients (pts) with brain metastases (BM), but disease progression in the brain is common. Sorafenib, a tyrosine kinase inhibitor with anti-VEGF activity, has demonstrated anti-tumor efficacy in MBC and radiosensitizing activity preclinically. [18F] 3'deoxy-3'-fluorothymidine (FLT) is a new PET tracer which correlates with cellular proliferation and may improve response assessment in the brain. Methods: A phase I trial of sorafenib with WBRT in MBC pts with BM was conducted using a 3+3 design. Sorafenib was given orally daily at the start of WBRT for a total of 21 days with 3 doses levels: 200mg, 400mg, and 600mg. The primary endpoints were to determine a maximum tolerated dose (MTD) and to evaluate safety and toxicity. The secondary endpoint was central nervous system progression-free survival (CNS-PFS). Macdonald Criteria were used for response assessment with serial MRI brain imaging. Key eligibility criteria include MBC with new or progressive ≥ 1cm BM, ECOG PS 0-2, non-escalating corticosteroid dose, and no other concurrent anti-tumor therapy except trastuzumab. In parallel, we conducted a correlative FLT-PET imaging study (baseline, 7-10 days (FU1), and 10-12 weeks (FU2) after the WBRT) to assess radiographic changes among pts receiving WBRT + sorafenib and in a separate WBRT only cohort. FLT standard uptake value (SUV) and kinetic parameter data were obtained. Results: 13 pts were treated in the dose escalation phase and evaluable for dose-limiting toxicity (DLT). The median age was 56 years (range: 43-77). There were 4 HER2 positive (31%) and 3 triple negative (23%) pts. 2 pts had prior stereotactic radiosurgery. DLTs were: Grade (G) 4 increased lipase at 200mg (1 pt) and G3 rash at 400mg (3 pts) level. MTD was determined to be 200mg. 10 pts were evaluable for response (at least 1 follow up brain imaging). The overall response rate was 70%: 4 complete responses (CR) + 3 partial responses. All 13 pts were evaluated for CNS PFS with a median follow up of 29.7 months (min 19.6, max 57.4mo). Median CNS-PFS was 8.2 months (95%CI: 3.4-31.8). Median OS was 15.4 months (95% CI: 3.4-NR). A total of 10 pts with WBRT and sorafenib and 5 pts with WBRT only were enrolled in the FLT-PET study: all 15 pts had baseline FLT PET, 14 with FU1, and 9 with FU2. 55 baseline lesions, 38 at FU1 and 15 at FU2 were observed and analyzed. All lesions with FLT uptake had MRI correlates. Decline in average SUVmax of ≥25% was seen in 9/10 (90%) of WBRT+sorafenib and 2/4(50%) of WBRT only pts at FU1. A complete disappearance of FLT uptake was noted in 1 pt at FU1 and 2 more pts at FU2. Conclusions: Concurrent WBRT with sorafenib appears safe at 200mg daily dose with a higher rate of CR compared to historical WBRT data. We are currently enrolling patients in the safety-expansion cohort. This combination should be considered for further efficacy evaluation. Additional analysis of FLT-PET as a complementary imaging modality to MRI is currently ongoing. Clinical trial registry: NCT01724606 and NCT01621906. Support: Bayer, Susan G Komen, ASCO Gianni Bonadonna Breast Cancer Award
Citation Format: Morikawa A, Jhaveri K, Grkovski M, Tang K, Humm JL, Holodny A, Beal K, Schoder H, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging in patients receiving WBRT with or without sorafenib [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-19-03.
Collapse
Affiliation(s)
- A Morikawa
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Jhaveri
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - M Grkovski
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Tang
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - JL Humm
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - A Holodny
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - K Beal
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - H Schoder
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| | - AD Seidman
- University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY
| |
Collapse
|
9
|
Zelefsky M, Yamada Y, Lis E, Schoder H, Lochansingh S, Shi W, Zhigang Z, Braunstein S, Kolesnick R, Fuks Z. Phase III Multi-Center, Prospective Randomized Trial Comparing High Dose Single Fraction Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Human Cancer. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Riaz N, Sherman E, Katabi N, Leeman J, Higginson D, Boyle J, Singh B, Morris L, Wong R, Tsai C, Schupak K, Gelblum D, McBride S, Hatzoglou V, Baxi S, Pfister D, Dave A, Humm J, Schoder H, Lee N. A Personalized Approach Using Hypoxia Resolution to Guide Curative-Intent Radiation Therapy Dose-Reduction to 30 Gy: A Novel De-escalation Paradigm for HPV-Associated Oropharynx Cancers Treated With Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Nehmeh S, Fox J, Schwartz J, Ballangrud A, Schoder H, Strauss H, Yu A, Gupta D, Hwang K, Powell S, Humm J, Ho A. A Pilot Study of Cardiac 13 N-Ammonia PET Imaging to Assess Early Cardiotoxicity Following Multibeam Intensity-Modulated Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
13
|
Batlevi C, Hamlin P, Matasar M, Gerecitano J, Drullinsky P, Hamilton A, Straus D, Horwitz S, Kumar A, Moskowitz C, Moskowitz A, Zelenetz A, Ahsanuddin S, Callan D, Freidin B, Porzio R, Soiffer J, Copeland A, Dang T, Rademaker J, Schoder H, Ni A, Younes A. PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_38] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- C. Batlevi
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Hamlin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Matasar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Drullinsky
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Hamilton
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Straus
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Horwitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - C. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Moskowitz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Zelenetz
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Ahsanuddin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - D. Callan
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - B. Freidin
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - R. Porzio
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Soiffer
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Copeland
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - T. Dang
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Rademaker
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schoder
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Ni
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
14
|
Scott D, Li H, Harvey Y, Chan F, Mottok A, Boyle M, Evens A, Schoder H, Straus D, Bartlett N, Sweetenham J, Barr P, Fanale M, Hsi E, Cook J, Kahl B, Leonard J, Friedberg J, Leblanc M, Steidl C, Gascoyne R, Rimsza L, Press O. THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_81] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- D.W. Scott
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - H. Li
- SWOG Statistical Centre; Fred Hutchison Cancer Research Centre; Seattle USA
| | - Y. Harvey
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - F. Chan
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - A. Mottok
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - M. Boyle
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - A.M. Evens
- Tufts Cancer Center; Tufts Medical Center; Boston USA
| | - H. Schoder
- Molecular Imaging and Therapy Service; Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - N.L. Bartlett
- Department of Medicine; Washington University School of Medicine; St. Louis USA
| | - J.W. Sweetenham
- Huntsman Cancer Institute; University of Utah; Salt Lake City USA
| | - P.M. Barr
- Wilmot Cancer Institute; University of Rochester; Rochester USA
| | - M.A. Fanale
- Department of Lymphoma/Myeloma; MD Anderson Cancer Center; Houston USA
| | - E.D. Hsi
- Department of Laboratory Medicine; Cleveland Clinic; Cleveland USA
| | - J.R. Cook
- Department of Laboratory Medicine; Cleveland Clinic; Cleveland USA
| | - B.S. Kahl
- Department of Medicine; Washington University School of Medicine; St. Louis USA
| | - J.P. Leonard
- Department of Medicine; Weill Cornell Medical College; New York USA
| | - J.W. Friedberg
- Wilmot Cancer Institute; University of Rochester; Rochester USA
| | - M. Leblanc
- SWOG Statistical Centre; Fred Hutchison Cancer Research Centre; Seattle USA
| | - C. Steidl
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - R.D. Gascoyne
- Centre for Lymphoid Cancer; British Columbia Cancer Agency; Vancouver Canada
| | - L.M. Rimsza
- Department of Laboratory Medicine and Pathology; Mayo Clinic; Scottsdale USA
| | - O.W. Press
- Clinical Research Division; Fred Hutchison Cancer Research Centre; Seattle USA
| |
Collapse
|
15
|
Sauter C, Matasar M, Schoder H, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba M, Portlock C, Straus D, Zelenetz A, McCall S, Miller S, Courtien A, Younes A, Moskowitz C. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C.S. Sauter
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - M.J. Matasar
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - H. Schoder
- Department of Radiology, Molecular Imaging and Therapy; Memorial Sloan Kettering Cancer Center; New York USA
| | - P. Drullinsky
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - J. Gerecitano
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Kumar
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Noy
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - M.L. Palomba
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.S. Portlock
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - D.J. Straus
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - A.D. Zelenetz
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.S. McCall
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - S.T. Miller
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - A.I. Courtien
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - A. Younes
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| | - C.H. Moskowitz
- Division of Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA
| |
Collapse
|
16
|
Kumar A, Casulo C, Advani R, Budde E, Barr P, Batlevi C, Chen R, Constine L, Courtien A, Dandapani S, Drullinsky P, Friedberg J, Hamlin P, Hoppe R, Matasar M, McArthur G, Miller S, Moskowitz A, Noy A, Schoder H, Straus D, Yang J, Younes A, Zelenetz A, Yahalom J, Moskowitz C. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED-SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Kumar
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - C. Casulo
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - R. Advani
- Hematology/Oncology, Stanford Cancer Institute; Stanford University; Stanford CA USA
| | - E. Budde
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - P.M. Barr
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - C.L. Batlevi
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - R. Chen
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - L.S. Constine
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - A.I. Courtien
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - S.V. Dandapani
- Hematology/Oncology; City of Hope National Medical Center; Duarte CA USA
| | - P. Drullinsky
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J.W. Friedberg
- Hematology/Oncology, Wilmot Cancer Institute; University of Rochester; Rochester NY USA
| | - P.A. Hamlin
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - R.T. Hoppe
- Hematology/Oncology, Stanford Cancer Institute; Stanford University; Stanford CA USA
| | - M.J. Matasar
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - G.N. McArthur
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - S.T. Miller
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A.J. Moskowitz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A. Noy
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - H. Schoder
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - D.J. Straus
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J. Yang
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A. Younes
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - A.D. Zelenetz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - J. Yahalom
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| | - C.H. Moskowitz
- Hematology/Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA
| |
Collapse
|
17
|
Schwartz J, Humm J, Nehmeh S, Schoder H. SU-E-J-263: Repeatability of SUV and Texture Parameters in Serial PET Studies. Med Phys 2015. [DOI: 10.1118/1.4924349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
18
|
Rosenberg S, Grewal R, Riaz N, Romesser P, Pena A, McBride S, Schoder H, Lee N. HPV-Positive Oropharyngeal Cancers: Midtreatment PET During Radiation Therapy and Implications for Treatment De-escalation. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Lanning R, Beattie B, Humm J, Zanzonico P, Rao S, Romesser P, Wong R, Sherman E, Schoder H, Lee N. Preliminary Results of a Prospective Trial of IMRT Dose De-escalation to Gross Nodal Disease in Human Papillomavirus (HPV)-Positive Oropharyngeal Carcinoma (OPC) Based on Assessment of Tumor Hypoxia Using 18F-FMISO PET Imaging. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2013.11.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Dharmarajan K, Wexler L, Tom A, Price A, Fox J, Schoder H, Gavane S, Meyers P, Wolden S. Positron Emission Tomography (PET) Response to Initial Chemotherapy and Radiation Therapy (RT) Predicts Local Control in Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
21
|
Abstract
PURPOSE The standardized uptake value (SUV) is a quantitative measure of FDG tumor uptake frequently used as a tool to monitor therapeutic response. This study aims to (i) assess the reproducibility and uncertainty of SUV max and SUV mean, due to purely statistical, i.e., nonbiological, effects and (ii) to establish the minimum uncertainty below which changes in SUV cannot be expected to be an indicator of physiological changes. METHODS Three sets of measurements were made using a GE Discovery STE PET/CT Scanner in 3D mode: (1) A uniform 68Ge 20 cm diameter cylindrical phantom was imaged. Thirty serial frames were acquired for durations of 3, 6, 10, 15, and 30 min. (2) Esser flangeless phantom (Data Spectrum, approximately 6.1 L) with fillable thin-walled cylinders inserts (diameters: 8, 12, 16, and 25 mm; height: approximately 3.8 mm) was scanned for five consecutive 3 min runs. The cylinders were filled with 18FDG with a 37 kBq/cc concentration, and with a target-to-background ratio (T/BKG) of 3/1. (3) Eight cancer patients with healthy livers were scanned approximately 1.5 h post injection. Three sequential 3 min scans were performed for one bed position covering the liver, with the patient and bed remaining at the same position for the entire length of the scan. Volumes of interest were drawn on all images using the corresponding CT and then transferred to the PET images. For each study (1-3), the average percent change in SUV mean and SUV max were determined for each run pair. Moreover, the repeatability coefficient was calculated for both the SUV mean and SUV max for each pair of runs. Finally, the overall ROI repeatability coefficient was determined for each pair of runs. RESULTS For the 68Ge phantom the average percent change in SUV max and SUV mean decrease as a function of increasing acquisition time from 4.7 +/- 3.1 to 1.1 +/- 0.6%, and from 0.14 +/- 0.09 to 0.04 +/- 0.03%, respectively. Similarly, the coefficients of repeatability also decrease between the 3 and 30 min acquisition scans, in the range of 10.9 +/- 3.9% - 2.6 +/- 0.9%, and 0.3 +/- 0.1% - 0.10 +/- 0.04%, for the SUV max and SUV mean, respectively. The overall ROI repeatability decreased from 18.9 +/- 0.2 to 6.0 +/- 0.1% between the 3 and 30 min acquisition scans. For the l8FDG phantom, the average percent change in SUV max and SUV mean decreases with target diameter from 3.6 +/- 2.0 to 1.5 +/- 0.8% and 1.5 +/- 1.3 to 0.26 +/- 0.15%, respectively, for targets from 8-25 mm in diameter and for a region in the background (BKG). The coefficients of repeatability for SUV max and SUV mean also decrease as a function of target diameter from 7.1 +/- 2.5 to 2.4 +/- 0.9 and 4.2 +/- 1.5 to 0.6 +/- 0.2, respectively, for targets from 8 mm to BKG in diameter. Finally, overall ROI repeatability decreased from 12.0 +/- 4.1 to 13.4 +/- 0.5 targets from 8 mm to BKG in diameter. Finally, for the measurements in healthy livers the average percent change in SUVmax and SUV mean were in the range of 0.5 +/- 0.2% - 6.2 +/- 3.9% and 0.4 +/- 0.1 and 1.6 +/- 1%, respectively. The coefficients of repeatability for SUV max and SUV men are in the range of 0.6 +/- 0.7% - 9.5 +/- 12% and 0.6 +/- 0.7% - 2.9 +/- 3.6%, respectively. The overall target repeatability varied between 27.9 +/- 0.5% and 41.1 +/- 1.0%. CONCLUSIONS The statistical fluctuations of the SUV mean are half as large as those of the SUV max in the absence of biological or physiological effects. In addition, for clinically applicable scan durations (i.e., approximately 3 min) and FDG concentrations, the SUV max and SUV mean have similar amounts of statistical fluctuation for small regions. However, the statistical fluctuations of the SUVmean rapidly decrease with respect tothe SUVmax as the statistical power of the data grows either due to longer scanning times or as the target regions encompass a larger volume.
Collapse
Affiliation(s)
- J Schwartz
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
| | | | | | | | | | | | | |
Collapse
|
22
|
Nehmeh SA, Haj-Ali AA, Qing C, Stearns C, Kalaigian H, Kohlmyer S, Schoder H, Ho AY, Larson SM, Humm JL. A novel respiratory tracking system for smart-gated PET acquisition. Med Phys 2010; 38:531-8. [DOI: 10.1118/1.3523100] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
23
|
Terezakis S, Schoder H, Kowalski A, McCann P, Schmidtlein C, Gonen M, Kirov A, Lovie S, Yahalom J. A Prospective Study of 18FDG-PET with CT scan Co-registration for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.1284] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Lee N, Jensen J, Schoder H, Wang Y, Fury M, Pfister DG, Stambuk H, Humm J, Koutcher J, Shukla-Dave A. Correlation of dynamic contrast enhanced magnetic resonance imaging (DCE MRI) with 18f-fluoromisonidazole positron emission and computed tomography ( 18F-FMISO PET/CT) in assessing tumor hypoxia in a series of head and neck cancer (HNC) patients with nodal metastases. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6083 Background: 18F-FMISO PET/CT is a noninvasive hypoxia imaging modality. Hypoxia can develop within the tumor which typically corresponds to regions with poor blood perfusion. DCE-MRI can yield results on tumor perfusion. The present study compares hypoxic and perfusion status of HNC with nodal metastases using DCE-MRI and 18F-FMISO PET/CT imaging. Methods: 13 HNC (7 base of tongue, 5 tonsil, 1 larynx) patients with nodal metastases underwent both DCE-MRI and 18F-FMISO PET/CT scans prior to chemoradiotherapy. MRI was performed on a 1.5 Tesla GE Excite scanner. DCE-MRI studies were acquired using a fast multi-phase spoiled gradient echo sequence. Antecubital vein catheters delivered a bolus of 0.1 mmol/kg Gd-DTPA at 2 cc/s. For 18F-FMISO PET/CT,∼10.0 mCi of 18F-FMISO was administered IV and images were acquired ∼2 hours later. PET images were reconstructed; CT data were used for attenuation correction. Region of interests (ROIs) were manually drawn by a neuroradiologist. Quantitative DCE-MRI analyses were done using the 2-compartment Tofts model. The analyses calculated the pixel Ktrans(distribution rate constant), ve(extravascular-extra-cellular volume fraction), and kep(redistribution rate constant). 18F-FMISO PET/CT images were analyzed and the uptake by the tumor was scored as: no uptake (score 0); moderate-severe uptake (score 1). Semi-quantitative analysis included standardized uptake value (SUV) measurements. Statistical significance was calculated using a 2-sided Student's t-test, with p < 0.05. Results: A total of 17 nodes were analyzed. For the nodes that showed no hypoxia on PET imaging (n = 7), the mean (±SD) values were: 18F-MISO SUV (1.1 ± 03), Ktrans(0.33 ± 0.18), ve(0.53 ± 0.23), and kep(0.66 ± 0.25). For the nodes that showed moderate to severe 18F-MISO uptake (n = 10) the values were: 18F-FMISO SUV (2.8 ± 08), Ktrans(0.24 ± 0.07), ve(0.61 ± 0.13), and kep (0.43 ± 0.17). A significant lower kep for nodes with 18F-MISO uptake (p = 0.042). Conclusions: Preliminary result supports the hypothesis that the hypoxic nodes are poorly perfused nodes (lower kep values) versus nodes with no hypoxia. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Lee
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Jensen
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. Schoder
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Y. Wang
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Fury
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - D. G. Pfister
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - H. Stambuk
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Humm
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | - J. Koutcher
- Memorial Sloan-Kettering Cancer Center, New York, NY
| | | |
Collapse
|
25
|
Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009; 53:158-166. [PMID: 19293764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We take advantage of the special characteristics of human tumors to image tumor response including predicting susceptibility to specific cancer therapies. The metabolic phenotype of malignancy, includes increased glycolysis (2-[(18)F]fluoro-2-D-deoxyglucose [FDG]), increased proliferation (2-[(18)F]fluoro-L-thymidine [FLT]), increased amino acid transport, as well as other functions such as fatty acid synthesis which have yet to be fully exploited. The endocrine dependent malignancies offer rich opportunities for selective imaging, including radioligands that have high affinity for hormone receptors, like androgen receptor (AR) (16Beta-[(18)F]16beta-[(18)F]fluoro-5alpha-dihydrotestoste-rone [FDHT]) and estrogen receptor (ER) ([(18)F]fluoroestradiol [FES]) and tissue specific transporters such as sodium iodide symporter (NIS) ((124)I). As knowledge of cancer biology has grown, it has become possible to develop tracers which image the client proteins involved in response to specific drugs, e.g. Gallium-68-Fab'2 herceptin for HER 2 effected by HSP 90 inhibitor drugs. More and more radiolabeled drugs will be used to explore the pharmacology of anticancer therapies, such as [(18)F]Desatinib. These may or may not be excellent imaging agents, but as analogs or even true tracers for specific anti-cancer drugs, noninvasive imaging through positron emission tomography will provide highly useful information, relating cancer pharmacology within the local tumor, to treatment response.
Collapse
Affiliation(s)
- S M Larson
- Nuclear Medicine Service, Donna and Benjamin M. Rosen Chair in Radiology, Molecular Pharmacology and Chemistry Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | |
Collapse
|
26
|
Terezakis S, Hunt M, Schmidtlein C, Gonen M, Kirov A, Gonzales A, Schoder H, Yahalom J. 18FDG-PET With CT Scan Co-Registration for Radiation Treatment Planning of Lymphoma Patients. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Schoder H, Tuttle RM. Reply: Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer? J Nucl Med 2007. [DOI: 10.2967/jnumed.107.044446] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
28
|
Abdelnour F, Nehmeh S, Pan T, Humm J, Vernon P, Schoder H, Rosenzweig K, Mageras G, Yorke E, Larson S, Erdi Y. SU-EE-A4-04: Phase and Amplitude Binning for 4D-CT Imaging. Med Phys 2006. [DOI: 10.1118/1.2240236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
29
|
Nehmeh SA, Erdi YE, Pan T, Yorke E, Mageras GS, Rosenzweig KE, Schoder H, Mostafavi H, Squire O, Pevsner A, Larson SM, Humm JL. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys 2005; 31:1333-8. [PMID: 15259636 DOI: 10.1118/1.1739671] [Citation(s) in RCA: 189] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
We report on the variability of the respiratory motion during 4D-PET/CT acquisition. The respiratory motion for five lung cancer patients was monitored by tracking external markers placed on the abdomen. CT data were acquired over an entire respiratory cycle at each couch position. The x-ray tube status was recorded by the tracking system, for retrospective sorting of the CT data as a function of respiration phase. Each respiratory cycle was sampled in ten equal bins. 4D-PET data were acquired in gated mode, where each breathing cycle was divided into ten 500 ms bins. For both CT and PET acquisition, patients received audio prompting to regularize breathing. The 4D-CT and 4D-PET data were then correlated according to their respiratory phases. The respiratory periods, and average amplitude within each phase bin, acquired in both modality sessions were then analyzed. The average respiratory motion period during 4D-CT was within 18% from that in the 4D-PET sessions. This would reflect up to 1.8% fluctuation in the duration of each 4D-CT bin. This small uncertainty enabled good correlation between CT and PET data, on a phase-to-phase basis. Comparison of the average-amplitude within the respiration trace, between 4D-CT and 4D- PET, on a bin-by-bin basis show a maximum deviation of approximately 15%. This study has proved the feasibility of performing 4D-PET/CT acquisition. Respiratory motion was in most cases consistent between PET and CT sessions, thereby improving both the attenuation correction of PET images, and co-registration of PET and CT images. On the other hand, in two patients, there was an increased partial irregularity in their breathing motion, which would prevent accurately correlating the corresponding PET and CT images.
Collapse
Affiliation(s)
- S A Nehmeh
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, Mageras GS, Schoder H, Vernon P, Squire O, Mostafavi H, Larson SM, Humm JL. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004; 31:3179-86. [PMID: 15651600 DOI: 10.1118/1.1809778] [Citation(s) in RCA: 277] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
We have reported in our previous studies on the methodology, and feasibility of 4D-PET (Gated PET) acquisition, to reduce respiratory motion artifact in PET imaging of the thorax. In this study, we expand our investigation to address the problem of respiration motion in PET/CT imaging. The respiratory motion of four lung cancer patients were monitored by tracking external markers placed on the thorax. A 4D-CT acquisition was performed using a "step-and-shoot" technique, in which computed tomography (CT) projection data were acquired over a complete respiratory cycle at each couch position. The period of each CT acquisition segment was time stamped with an "x-ray ON" signal, which was recorded by the tracking system. 4D-CT data were then sorted into 10 groups, according to their corresponding phase of the breathing cycle. 4D-PET data were acquired in the gated mode, where each breathing cycle was divided into ten 0.5 s bins. For both CT and PET acquisitions, patients received audio prompting to regularize breathing. The 4D-CT and 4D-PET data were then correlated according to respiratory phase. The effect of 4D acquisition on improving the co-registration of PET and CT images, reducing motion smearing, and consequently increase the quantitation of the SUV, were investigated. Also, quantitation of the tumor motions in PET, and CT, were studied and compared. 4D-PET with matching phase 4D-CTAC showed an improved accuracy in PET-CT image co-registration of up to 41%, compared to measurements from 4D-PET with clinical-CTAC. Gating PET data in correlation with respiratory motion reduced motion-induced smearing, thereby decreasing the observed tumor volume, by as much as 43%. 4D-PET lesions volumes showed a maximum deviation of 19% between clinical CT and phase- matched 4D-CT attenuation corrected PET images. In CT, 4D acquisition resulted in increasing the tumor volume in two patients by up to 79%, and decreasing it in the other two by up to 35%. Consequently, these corrections have yielded an increase in the measured SUV by up to 16% over the clinical measured SUV, and 36% over SUV's measured in 4D-PET with clinical-CT Attenuation Correction (CTAC) SUV's. Quantitation of the maximum tumor motion amplitude, using 4D-PET and 4D-CT, showed up to 30% discrepancy between the two modalities. We have shown that 4D PET/CT is clinically a feasible method, to correct for respiratory motion artifacts in PET/CT imaging of the thorax. 4D PET/CT acquisition can reduce smearing, improve the accuracy in PET-CT co-registration, and increase the measured SUV. This should result in an improved tumor assessment for patients with lung malignancies.
Collapse
Affiliation(s)
- S A Nehmeh
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Dotan ZA, Kattan MW, Bianco FJ, Rabbani F, Eastham JA, Scher HI, Hui-Ni C, Schoder H, Hricak H, Scardino PT. What is the probability of a positive bone scan (+BS) in patients with a rising PSA after radical prostatectomy (RP): A new nomogram. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
32
|
Rosenzweig K, Erdi Y, Schoder H, Akhurst T, Larson S, Leibel S. Positron emission tomography after three-dimensional conformal radiation therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2001. [DOI: 10.1016/s0360-3016(01)01988-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|